Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B

Gene Therapy

Volumn 11, Issue 2, 2004, Pages 204-213

  Harding, T C ^a   Koprivnikar, K E ^a   Tu, G H ^a   Zayek, N ^a   Lew, S ^a   Subramanian, A ^a   Sivakumaran, A ^a   Frey, D ^a   Ho, K ^a   VanRoey, M J ^a   Nichols, T C ^b   Bellinger, D A ^b   Yendluri, S ^a   Waugh, J ^a   McArthur, J ^a   Veres, G ^a   Donahue, B A ^a  

^a CELL GENESYS INC   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adeno associated virus; Factor IX; Hemophilia B; Intravenous; Intron

Indexed keywords

BETA GLOBIN; BLOOD CLOTTING FACTOR 9; CIS ACTING ELEMENT; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING DISORDER; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MODEL; DOG; GENE CASSETTE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HEMOPHILIA B; HEPATITIS VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; INTRON; LIVER; LIVER VEIN; MALE; METABOLISM; METHODOLOGY; MOUSE; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TAIL; TRANSCRIPTION REGULATION; TRANSGENE; VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; DEPENDOVIRUS; DOGS; FACTOR IX; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA B; HEPATIC VEINS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LIVER; MICE; TAIL; TRANSDUCTION, GENETIC;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS 2; ANIMALIA; CANIS FAMILIARIS; MARMOTA MONAX; PARVOVIRUS; WOODCHUCK HEPATITIS B VIRUS;

EID: 10744220531     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302142     Document Type: Article

References (33)

1. Herzog RW et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997; 94: 5804-5809.
2. Snyder RO et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16: 270-276.
3. Snyder RO et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 1999; 5: 64-70.
4. Chao H et al. Persistent expression of canine factor IX in hemophilia B canines. Gene Therapy 1999; 6: 1695-1704.
5. Wang L et al. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci USA 1999; 96: 3906-3910.
6. Wang L et al. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther 2000; 1: 154-158.
7. Chao H et al. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2000; 2: 619-623.
8. Nathwani AC et al. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood 2002; 100: 1662-1669.
9. Kay MA et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24: 257-261.
10. Ge Y, Powell S, Van Roey M, McArthur JG. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. Blood 2001; 97: 3733-3737.
11. Nathwani AC et al. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood 2001; 97: 1258-1265.
12. Herzog RW et al. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther 2001; 4: 192-200.
13. Kay MA et al. A proposed rAAV-liver-directed clinical trial for hemophilia B. Mol Ther 2001; 5: S33 (abstr. 85).
14. Nakai H, Iwaki Y, Kay MA, Couto LB. Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. J Virol 1999; 73: 5438-5447.
15. Mingozzi F et al. Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector. J Virol 2002; 76: 10497-10502.
16. Brinster RL et al. Introns increase transcriptional efficiency in transgenic mice. Proc Natl Acad Sci USA 1988; 85: 836-840.
17. Palmiter RD et al. Heterologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci USA 1991; 88: 478-482.
18. Choi T, Huang M, Gorman C, Jaenisch R. A generic intron increases gene expression in transgenic mice. Mol Cell Biol 1991; 11: 3070-3074.
19. Rodriguez MH et al. Expression of coagulation factor IX in a haematopoietic cell line. Thromb Haemost 2002; 87: 366-373.
20. Miao CH et al. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol Ther 2000; 1: 522-532.
21. Donello JE, Loeb JE, Hope TJ. Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J Virol 1998; 72: 5085-5092.
22. Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999; 73: 2886-2892.
23. Loeb JE et al. Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: implications for gene therapy. Hum Gene Ther 1999; 10: 2295-2305.
24. Huang Y, Wimler KM, Carmichael GG. Intronless mRNA transport elements may affect multiple steps of pre-mRNA processing. EMBO J 1999; 18: 1642-1652.
25. Choi EA, Hope TJ. The role of poly(A) tail stability in the ability of the woodchuck hepatitis virus posttranscriptional regulatory element to stimulate gene expression. Mol Ther 2002; 5: S142 (abstr. 439).
26. Ill CR et al. Optimization of the human factor VIII complementary DNA expression plasmid for gene therapy of hemophilia A. Blood Coagul Fibrinolysis 1997; 8 (Suppl 2): S23-S30.
27. Hafenrichter DG et al. Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes. Blood 1994; 84: 3394-3404.
28. Ponnazhagan S et al. Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. Gene 1997; 190: 203-210.
29. Sanlioglu S et al. Rate limiting steps of AAV transduction and implications for human gene therapy. Curr Gene Ther 2001; 1: 137-147.
30. Herzog RW et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5: 56-63.
31. Gao GP et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 11854-11859.
32. Wang L et al. High level expression of canine factor IX in hemophilia B dogs after readministration of AAV2/5 vectors. Mol Ther 2002; 5: S83 (abstr. 250).
33. Snyder RO, Xiao X, Samulski RJ. Production of recombininant adeno-associated viral vectors. In: Dracapoli NC, Haines JL, Korf BR, Moir DT, Mortan CC, Seidman CE, Seidman JG, Smith DR (eds). Current Protocols in Human Genetics. John Wiley & Sons: New York, 1996.